Century Therapeutics (IPSC) shares were up more than 8% in recent Tuesday trading after the company reported Q3 results that beat market expectations.
The firm posted a Q3 net loss of $0.37 per diluted share, narrowing from $0.55 loss a year ago. Analysts polled by Capital IQ expected $0.45 loss per share.
Revenue for the quarter ended Sept. 30 was $791,000, compared with $148,000 a year earlier. Analysts polled by Capital IQ expected $550,000.
The company said it expects its funds will support operations into the H2 of 2026.
Price: 1.37, Change: +0.11, Percent Change: +8.33
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。